PRESS RELEASE | Hampton, UK / Basel, Switzerland, March 01, 2022
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage company focused on discovering and developing ground-breaking RNA-based therapeutics.